MTA Antibody

What are MTA antibodies and what proteins do they target?

MTA antibodies are research reagents that specifically bind to different MTA family proteins, including:

• MTA1, MTA2, MTA3: Members of the metastasis-associated protein family that function as transcriptional corepressors in histone deacetylase complexes like NuRD

• MTAP: S-methyl-5'-thioadenosine phosphorylase, which catalyzes the reversible phosphorylation of MTA to adenine and 5-methylthioribose-1-phosphate

• MTA/METTL3: Methyltransferase A, a component of the methyltransferase complex (MTC) involved in m6A RNA modification

These proteins play crucial roles in epigenetic regulation, RNA modification, and metabolic pathways relevant to cancer biology and gene expression regulation .

What applications are MTA antibodies suitable for?

Based on validated applications from multiple sources, MTA antibodies are typically suitable for:

The specific applications have been validated for different antibodies, with Western blotting being the most commonly supported technique across all MTA antibody types .

How should I validate an MTA antibody for my specific research application?

A systematic antibody validation approach should include:

• Expression correlation: Confirm that antibody signal correlates with known mRNA expression patterns across cell lines. For example, when screening antibodies against NCI60 cell lines, the expression profile should match previously identified mRNA signal profiles in databases like "Compare"

• Knockout/knockdown controls: Test the antibody in MTAP-null or MTA-knockdown models to verify specificity. The HAP1 MTAP WT and MTAP-null isogenic cell line pair (Horizon Discovery HZGHC004894c005) is a validated control system for MTAP antibody validation

• Signal quantification: For Western blot validation, use predicted band size (e.g., 31 kDa for MTAP, 75 kDa for MTA2, 68 kDa for MTA3) to confirm specificity

• Cross-reactivity assessment: Determine species reactivity across human, mouse, and other relevant species by testing in appropriate cell lines

• Tissue microarray (TMA) validation: For IHC applications, validate using multi-tumor tissue microarrays to establish staining patterns across different tissue types

What controls should I include when using MTA antibodies in immunoprecipitation experiments?

For robust IP experiments with MTA antibodies:

• Input control: Always include an input sample (5-10% of starting material) to verify protein presence before IP

• Isotype control: Use matched IgG from the same species as your MTA antibody

• RNase treatment control: When studying RNA-binding proteins like MTA/METTL3, perform parallel IPs with and without RNase A treatment to determine if interactions are RNA-dependent or direct protein-protein interactions

• Reciprocal IP: If studying protein complexes (e.g., MTC or NuRD), perform reciprocal IPs with antibodies against known interaction partners. For example, researchers have shown that "an anti-MTA antibody precipitated both GFI1 and CHD4 in THP-1 cells" confirming the interaction between these proteins

• Protein-specific controls: For MTAP antibodies, use paired MTAP-WT and MTAP-null cell lines like the HAP1 isogenic pair

How can I use MTA antibodies to study the PRMT5- MTA complex in MTAP-deleted cancers?

The PRMT5- MTA complex has emerged as a synthetic lethal drug target for MTAP-deleted cancers . To study this complex:

• Biochemical assays: Implement the FlashPlate PRMT5–MEP50 radiolabeled methyltransferase assay with and without MTA supplementation (typically 2 μM MTA and 1 μM SAM) to investigate compound effects on the PRMT5- MTA complex

• Cellular assays: Use an MTAP isogenic cell line pair to evaluate cellular responses. The HAP1 MTAP WT and MTAP-null viability assay involves:

  • Plating cells at 700-1400 cells/well in 384-well plates

  • Treating with compounds for 7 days in a humidified 5-10% CO₂ incubator

  • Assessing viability with appropriate detection methods

• Antibody-based detection: Use MTAP antibodies to confirm MTAP deletion status in cell lines and patient samples, as proper stratification is essential for studying synthetic lethality

• Target engagement: Use MTA antibodies to monitor formation of the PRMT5- MTA complex in cells following drug treatment

What are the key considerations when using MTA antibodies for studying m6A RNA modification pathways?

When investigating m6A pathways with MTA (METTL3) antibodies:

• Nuclear fraction preparation: Since m6A modification occurs in the nucleus, prepare nuclear fractions for immunoprecipitation with anti-MTA antibodies

• MeRIP integration: Combine Methylated RNA Immunoprecipitation (MeRIP) assays with MTA antibody ChIP to correlate MTA binding with m6A deposition sites. In studies, "IPs were conducted with the nuclear fraction using an anti-MTA antibody" to investigate m6A modification sites

• Complex interaction studies: Use antibodies against both MTA and MTB to study their interactions with the microprocessor complex components (including SE, HYL1, and DCL1) involved in miRNA processing

• Biological validation: After identifying m6A-modified transcripts through MTA antibody IP, validate the functional consequences using genetic models (e.g., mta mutants)

• Combinatorial approaches: Consider combining MTA antibody IP with HPLC-MS quantification of m6A levels to link antibody-identified binding sites with actual methylation events

What are the recommended conditions for using MTA antibodies in Western blotting?

Based on published protocols with MTA antibodies:

• Sample preparation: For MTA2, use SDS-PAGE with 7.5-12% gels depending on the specific MTA protein (MTA2: 75 kDa, MTA3: 68 kDa, MTAP: 31 kDa)

• Antibody dilution:

  • Anti-MTAP: 1/1000 dilution (ab96231)

  • Anti-MTA2: 1/1000 dilution (CST #15793)

  • Anti-MTA3: 1/1000 dilution (ab227626)

• Sample loading: Load 30 μg of whole cell lysate (e.g., from A431, Jurkat, or similar cell lines)

• Detection systems: Use chemiluminescence or fluorescence-based detection systems; for multiplexing, NIR fluorescent imagers like LiCor Odyssey are recommended

• Positive controls: Include cell lines known to express the target MTA protein (e.g., A431 for MTAP, Jurkat for MTA3)

How should I optimize MTA antibodies for immunohistochemistry applications?

For IHC applications with MTA antibodies (particularly MTAP):

• Antigen retrieval: Use heat-induced epitope retrieval with citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Antibody titration: Determine optimal antibody concentration through titration series. The goal is to achieve "maximum dynamic range of staining - negative to positive in different cell lines, combined with uniformity of staining within cell lines at the minimum dilution"

• Signal development: Use 3,3'-diaminobenzidine (DAB) as chromogen with light hematoxylin counterstaining

• Scoring system: Implement a standardized scoring system (0, +1, +2, +3 for no, weak, moderate, and strong staining) based on the fraction of positively stained cells

• Validation controls: Include both positive and negative control tissues on the same slide to ensure staining consistency

How can I conjugate MTA antibodies with fluorophores for imaging applications?

For conjugating MTA antibodies to fluorophores (e.g., PE):

• Buccutite™ conjugation technology: This method allows for controlled antibody labeling:

  • Add 5 μL of Reaction Buffer to 100 μL of antibody solution

  • Add the antibody solution to Buccutite™ MTA vial and mix

  • Incubate at room temperature, then remove free Buccutite™ MTA using a spin column

  • Mix MTA-activated antibody with fluorophore (e.g., Buccutite™ FOL-PE) and incubate for 1 hour

• Validation: Test conjugated antibodies in known positive and negative cell lines using flow cytometry or microscopy

What are the approaches for using low-affinity, high-specificity MTA antibodies in super-resolution microscopy?

Innovative approaches for super-resolution imaging with MTA antibodies include:

• Fv-Clasp and vHH formats: These antibody formats provide high specificity with controlled affinity

• Sequential imaging: For multiplexed super-resolution imaging, use antibodies with controlled off-rates that allow sequential probing and washing steps

• Epitope tag targeting: Use anti-epitope tag antibodies with controlled affinity to target MTA proteins expressed with epitope tags

• Validation by synapse counting: In neuronal imaging applications, validate that "the number of times the novel high-specificity low-affinity antibody probes labeled the target molecules at each synapse was comparable to the number of each molecule estimated to localize at a synapse"

How can MTA antibodies be used to study synthetic lethality in cancer research?

MTA antibodies are valuable tools in synthetic lethality research:

• MTAP deletion stratification: Use MTAP antibodies to identify MTAP-deleted cancer cells which are susceptible to PRMT5 inhibition. The PRMT5- MTA complex has emerged as a synthetic lethal target in these cells

• Combinatorial assays: Combine MTAP antibody-based detection with PRMT5 inhibitor treatment in paired isogenic cell lines:

  • Use MTAP antibodies in Western blot or IHC to confirm deletion status

  • Perform cell viability assays with PRMT5 inhibitors (e.g., GSK3326595)

  • Compare IC₅₀ values between MTAP-deleted and MTAP-intact cells

• Target engagement: Use MTA antibodies to monitor formation of the PRMT5- MTA complex and effects of MTA-cooperative PRMT5 inhibitors

What role do MTA antibodies play in studying the interplay between m6A modification and miRNA processing?

MTA antibodies are crucial for investigating the connection between m6A RNA modification and miRNA biogenesis:

• Complex detection: Anti-MTA antibodies can immunoprecipitate complexes containing microprocessor components (SE, HYL1, DCL1), revealing the physical interaction between the methyltransferase complex and miRNA processing machinery

• Mechanistic studies: Researchers have used MTA antibodies to demonstrate that "the MTC might associate with the key components of the microprocessor" and that this interaction is mediated by MTB

• Quantitative analysis: Combining MTA antibody IP with small RNA-seq has shown that "a total of 89 miRNAs as accumulating to lower levels in mta relative to Col-0, all of which were also less abundant in se-1 compared to Col-0"

• Structural insights: MTA antibodies help elucidate how "MTC could tether the microprocessor to chromatin, facilitating co-transcriptional pri-miRNA processing"

• Phase separation studies: Recent research using MTA antibodies revealed that "SE could utilize its liquid-like phase behaviors to maintain the MTB solubility, allowing the uptake of RNA substrate by MTC to fulfill the enzymatic activity"